PEB Pacific Edge Ltd

Pacific Edge Diagnostics Notified of CMS LCD Coverage for Cxbladder®

Pacific Edge Diagnostics Notified of CMS LCD Coverage for Cxbladder®
EN
12/10/2020

Underlying

PEBPacific Edge Ltd

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pacific Edge Ltd

Free Trial
PEB Pacific Edge Lt...

Pacific Edge Limited: 1 director

A director at Pacific Edge Limited bought 397,942 shares at 0.136NZD and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...

PEB PACIFIC EDGE LTD
08/03/23 August 3, 2023 1 EN
Free Trial
PEB Pacific Edge Lt...

Increased risk weighs on PACIFIC EDGE, penalising its rating down to ...

The independent financial analyst theScreener just lowered the general evaluation of PACIFIC EDGE (NZ), active in the Biotechnology industry. As regards its fundamental valuation, the title still shows 0 out of 4 possible stars. Its market behaviour, however, has slightly deteriorated and will be qualified as risky moving forward. theScreener considers that these new qualifications justify an overall rating downgrade to Negative. As of the analysis date February 8, 2022, the closing price was NZ...

PEB PACIFIC EDGE LTD
02/09/22 February 9, 2022 1 EN
Sean Conroy
  • Sean Conroy
PEB Pacific Edge Lt...

Pacific Edge - Termination of coverage

Edison Investment Research is terminating coverage on Kcell Joint Stock Company (KCEL), Locate Bio, Pacific Edge (PEB), Tungsten Corporation (TUNG) and VEF (VEMF). Please note you should no longer rely on any previous research or estimates for these companies. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.

PEB PACIFIC EDGE LTD
07/27/21 July 27, 2021 1 EN
Sean Conroy
  • Sean Conroy
PEB Pacific Edge Lt...

Pacific Edge - Operating revenue up 46% on strong US growth

The company recently reported results for H1 FY21, featuring a 46% y-o-y increase in Cxbladder sales to NZ$3.3m. The US business grew 46% to NZ$2.9m and was assisted by the inclusion of Cxbladder into a local coverage determination (LCD) enabling reimbursement at US$760 per test from the US Centers for Medicare and Medicaid Services (CMS) on all tests after 1 July (corresponding to the second half of H1 FY21). The outlook for growth in the US business is strong due to the change in reimbursement...

PEB PACIFIC EDGE LTD
01/25/21 January 25, 2021 6 EN
 PRESS RELEASE
Free
PEB Pacific Edge Lt...

Pacific Edge Diagnostics Notified of CMS LCD Coverage for Cxbladder®

Pacific Edge Diagnostics Notified of CMS LCD Coverage for Cxbladder®

October 12, 2020 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch